Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10528334 | 0.83 | — | — | |
| SCHEMBL3279381 | 0.80 | ALDH1A1 (0.55) | POLBSMN1; SMN2ALDH1A1CYP1A2 | |
| Acetic Acid SCHEMBL28739551 | 0.79 | LTA4H (0.56) | HRH3KDM4ELTA4HPOLBKEAP1 | |
| SCHEMBL631252 | 0.78 | L3MBTL1 (0.70) | HRH3KDM4ELTA4HPOLBKEAP1 | |
| SCHEMBL56046 | 0.77 | HRH3 (0.63) | HRH3KDM4ELTA4HKEAP1NFE2L2 | |
| Hydrochloric Acid SCHEMBL5412869 | 0.77 | L3MBTL1 (0.68) | HRH3KDM4ELTA4HPOLBKEAP1 | |
| SCHEMBL12010844 | 0.76 | HRH3 (0.58) | HRH3KDM4ELTA4HPOLBKEAP1 | |
| SCHEMBL6057420 | 0.76 | ESR1 (0.59) | HRH3KDM4ELTA4HPOLBKEAP1 | |
| SCHEMBL7150669 | 0.75 | HRH3 (0.62) | HRH3KDM4ELTA4HPOLBKEAP1 | |
| SCHEMBL3600523 | 0.75 | KEAP1 (0.51) | HRH3KDM4ELTA4HPOLBKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030008849-A1 | Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors | LEVIN JEREMY I (US) | 2003-01-09 | — | — | US | claimed |
| US-20040033988-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH (US) | 2004-02-19 | — | — | US | disclosed |
| US-20030008849-A1 | Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors | LEVIN JEREMY I (US) | 2003-01-09 | — | — | US | disclosed |
| EP-1144368-A2 | ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000044709-A2 | ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008849-A1 | Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | HRH3 1098/4885KDM4E 3928/4885LTA4H 1095/4885 |
| US-20040033988-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | HRH3 1098/4885KDM4E 3928/4885LTA4H 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.